Dr. Tomohiro Fujii obtained his first Ph.D. degree from Waseda University in 2014 and commenced his scientific career as a researcher at Ajinomoto Co., Inc. in the same year. After working as a researcher for several years, he became an ADC researcher at Ajinomoto Bio-Pharma Services, San Diego in 2020. In 2021, he returned to Ajinomoto Co., Inc. as an ADC researcher, and is currently leading all the technological aspects of the AJICAP project. Dr. Fujii’s research interests focus on various aspects of ADC technology, including novel conjugation, process development, and analysis.
ADC Review, Journal of Antibody-drug Conjugates (ISSN 2327-0152) is an international peer-reviewed publication designed to serve the needs of a diverse community of individuals including academia, life sciences, pharma, research, clinicians and physicians. Along with regulatory affairs, we also cover government authorities and representatives from payers to policymakers.